Posted by Michael Wonder on 27 Nov 2023
Formycon announces EMA submission for FYB203, a biosimilar candidate to Eylea (aflibercept)
27 November 2023 - Formycon and its license partner Klinge Biopharma announce that the marketing authorisation application for FYB203, a biosimilar candidate for Eylea (aflibercept) has been submitted to the EMA.
“Our latest MAA submission once again demonstrates the high performance and reliability of the entire #TeamFormycon. We are very pleased that with FYB203 we have filed our second biosimilar candidate in the ophthalmology space that is likely to become even more important in the coming years in light of the ageing population.”, says Formycon CEO Dr. Stefan Glombitza.
